Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer | Zendy

Azzour D. Hazzan | Zendy; Hitesh H. Shah | Zendy; Susana Hong | Zendy; Vipulbhai Sakhiya | Zendy; Rimda Wanchoo | Zendy; Steven Fishbane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer

Author(s) -

Azzour D. Hazzan,

Hitesh H. Shah,

Susana Hong,

Vipulbhai Sakhiya,

Rimda Wanchoo,

Steven Fishbane

Publication year - 2014

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2013.528

Subject(s) - medicine , anemia , nephrology , kidney disease , erythropoietin , intensive care medicine , malignancy , cancer , epoetin alfa , kidney cancer , population , disease , oncology , clinical trial , environmental health

Treatment of anemia remains an important component in the care of patients with nondialysis chronic kidney disease (CKD) and end-stage renal disease (ESRD). Erythropoietin-stimulating agents (ESAs) remains a key anemia treatment strategy in this patient population. However, anemia management in this group can become more complicated by prior or current history of malignancy. There has been a great deal of work both scientifically and in clinical trials in oncology that have revealed certain concerns and risks of ESA use in patients with cancer. In this review, we will bring together knowledge from nephrology and oncology literature to help nephrologists understand the implications for ESA treatment when CKD/ESRD is complicated by cancer. We also suggest an approach to the management of anemia in this patient group with active or previous malignancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research